Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Relay rapeutics - What They Never Told You

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2022

Analyst Ratings for Relay Therapeutics

Analyst Ratings for Relay Therapeutics

Over the past 3 months, 4 analysts have published their opinion on Relay Therapeutics (NASDAQ:RLAY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Preview: Relay Therapeutics's Earnings

Relay Therapeutics (NASDAQ:RLAY) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Relay Therapeutics will report an earnings per share (EPS) of $-0.62.

1

Organisations

American Express

Palo Alto Networks

CrowdStrike Holdings

Lululemon Athletica

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play